How did the Cochlear (ASX:COH) share price respond last earnings season?

Shares in the hearing aid manufacturer are on the move in anticipation of its FY21 earnings tomorrow

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price has stepped into the green in afternoon trade on Thursday.

Shares in the hearing aid manufacturer are exchanging hands at $257.12 apiece, a 1.23% jump from yesterday's close of $253.

The Cochlear share price is on the move as the company is due to report its FY21 earnings on Friday.

In addition, given its strength on the charts this year to date, it's worthwhile investigating what happened to the Cochlear share price after the company's last earnings report. Let's do just that.

An older woman tries to listen by cupping her ear.

Image source: Getty Images

What did Cochlear deliver back in February?

The company recognised a 4% decline in first-half sales to $742 million. This carried through to a 6% decline in underlying net profit, to $125 million.

Moreover, the company saw a recovery in its key markets, including the US, Japan, Korea, and China. Furthermore, Cochlear sales were strong in Europe in the first half.

In addition, Cochlear declared a $1.15 per share dividend, which was a 28% down-step from the year prior.

Given this momentum, Cochlear provided full-year net profit guidance of $225 million to $245 million, calling for a 46% to 59% year-on-year increase, respectively.

What happened to the Cochlear share price?

In a negative for the Cochlear share price, investors punished the company on the charts in the two weeks following the release. It was trading at $221 per share at the close on 19 February.

It appeared the market received a decline in sales and net profit with closed arms. What's more, the dividend haircut didn't go down too well, either.

As a result, the Cochlear share price immediately took a hit, wiping $21 per share or 9.5% off the charts.

However, in a demonstration of resiliency, Cochlear shares have since climbed back north at a tremendous pace.

To illustrate, since the low quoted above of $200 on 5 May, Cochlear has gained $57 per share, or a further 28.5%.

Given there's been no market-sensitive information for the company since that time, it may be that investors are baking in the 46% – 59% in growth profit guidance for FY22 that management alluded to back in February.

Nonetheless, Cochlear shareholders will be hoping the company delivers on its guidance targets. Especially considering how the market reacted to its previous earnings report.

At the current price, Cochlear has a market capitalisation of $16.7 billion, and has climbed 35% since January 1.

For context, the S&P/ASX 200 index (ASX: XJO) has posted a return of around 14% this year to date.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal

Pro Medicus has renewed its major contract with Northwestern Medicine, locking in higher fees and strengthened client ties for the…

Read more »

Rising healthcare ASX share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal

Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies.

Read more »

Two health workers taking a break.
Healthcare Shares

It could be time to buy-low on this ASX small-cap stock according to brokers

This ASX healthcare stock keeps attracting positive ratings, with one broker now tipping a 268% rise.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Healthcare Shares

Should you buy Telix shares after its big US news?

Is this milestone a reason to invest? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Up 31% in a month, why are Telix shares lifting off again on Friday?

ASX investors are piling into Telix shares today. But why?

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Where is the value amongst ASX healthcare shares?

These three stocks are worth monitoring.

Read more »